- The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment
-
Kim SH, Lim YJ
- KMID: 2525070
- Intest Res.
- 2022 Jan;20(1):31-42.
- doi: 10.5217/ir.2021.00034
The role of gut microbiome-intestinal immune complex in the development of colorectal cancer and its progression is well recognized. Accordingly, certain microbial strains tend to colonize or vanish in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
-
Park J
- KMID: 2525067
- Intest Res.
- 2022 Jan;20(1):1-2.
- doi: 10.5217/ir.2021.00170
-
- CITED
-
- Close
- SHARE
-
- Close
- Management of inflammatory bowel disease in the COVID-19 era
-
Kim KO, Jang BI
- KMID: 2525068
- Intest Res.
- 2022 Jan;20(1):3-10.
- doi: 10.5217/ir.2020.00156
During the coronavirus disease 2019 (COVID-19) pandemic, many unpredictable changes have occurred in the medical field. Risk of COVID-19 does not seem to increase in patients with inflammatory bowel disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
-
Singh AK, Jena A, Kumar-M P, Jha DK, Sharma V
- KMID: 2525080
- Intest Res.
- 2022 Jan;20(1):134-143.
- doi: 10.5217/ir.2020.00108
Background/Aims: Coronavirus disease 2019 (COVID-19) is recognized to have variable clinical manifestations. The clinical presentation of patients with inflammatory bowel disease (IBD) having COVID-19 is unclear. Methods: We identified articles reporting... -
- CITED
-
- Close
- SHARE
-
- Close
- Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
-
Koroku M, Omori T, Kambayashi H, Murasugi S, Kuriyama T, Ikarashi Y, Yonezawa M, Arimura K, Karasawa K, Hanafusa N, Kawana M, Tokushige K
- KMID: 2525082
- Intest Res.
- 2022 Jan;20(1):150-155.
- doi: 10.5217/ir.2020.00148
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have... -
- CITED
-
- Close
- SHARE
-
- Close
- An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia
-
Shafiee NH, Razalli NH, Mokhtar NM, Tan E, Ali RAR
- KMID: 2525079
- Intest Res.
- 2022 Jan;20(1):124-133.
- doi: 10.5217/ir.2020.00050
Background/Aims: Substantial proportions of patients with constipation-predominant irritable bowel syndrome (IBS-C) linked their symptoms with particular intake of foods. However, there is lack of current data regarding the intake among... -
- CITED
-
- Close
- SHARE
-
- Close
- An integrative review of physical activity in adults with inflammatory bowel disease
-
Davis SP, Crane PB, Bolin LP, Johnson LA
- KMID: 2525071
- Intest Res.
- 2022 Jan;20(1):43-52.
- doi: 10.5217/ir.2020.00049
Adults with inflammatory bowel disease (IBD) search for self-management strategies to manage their symptoms and improve their quality of life (QOL). Physical activity (PA) is one of the self-management strategies... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of thiopurines in inflammatory bowel disease: an update
-
Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A
- KMID: 2525069
- Intest Res.
- 2022 Jan;20(1):11-30.
- doi: 10.5217/ir.2020.00155
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
-
Barberio B, Savarino EV, Card T, Canova C, Baldisser F, Gubbiotti A, Massimi D, Ghisa M, Zingone F
- KMID: 2525078
- Intest Res.
- 2022 Jan;20(1):114-123.
- doi: 10.5217/ir.2021.00037
Background/Aims: Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a... -
- CITED
-
- Close
- SHARE
-
- Close
- Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
-
Mahajan R, Singh A, Kedia S, Kaur K, Midha V, Sahu P, Mehta V, Singh D, Bansal N, Dharni K, Kaushal S, Ahuja V, Sood A
- KMID: 2525073
- Intest Res.
- 2022 Jan;20(1):64-71.
- doi: 10.5217/ir.2020.00100
Background/Aims: Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high... -
- CITED
-
- Close
- SHARE
-
- Close
- The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom
-
Crooks B, Misra R, Arebi N, Kok K, Brookes MJ, McLaughlin J, Limdi JK
- KMID: 2525072
- Intest Res.
- 2022 Jan;20(1):53-63.
- doi: 10.5217/ir.2020.00079
Background/Aims: Epidemiological associations have implicated factors associated with Westernization, including the Western diet, in the development of inflammatory bowel disease (IBD). The role of diet in IBD etiopathogenesis, disease control... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
-
Sakurai K, Furukawa S, Katsurada T, Otagiri S, Yamanashi K, Nagashima K, Onishi R, Yagisawa K, Nishimura H, Ito T, Maemoto A, Sakamoto N
- KMID: 2525075
- Intest Res.
- 2022 Jan;20(1):78-89.
- doi: 10.5217/ir.2020.00124
Background/Aims: Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine... -
- CITED
-
- Close
- SHARE
-
- Close
- Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
-
Poylin VY, Serrato JC, Pastrana Del Valle J, Feuerstein JD
- KMID: 2525074
- Intest Res.
- 2022 Jan;20(1):72-77.
- doi: 10.5217/ir.2020.00117
Background/Aims: Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery.... -
- CITED
-
- Close
- SHARE
-
- Close
- Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
-
Con D, Andrew B, Nicolaides S, van Langenberg DR, Vasudevan A
- KMID: 2525077
- Intest Res.
- 2022 Jan;20(1):101-113.
- doi: 10.5217/ir.2020.00146
Background/Aims: The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity
-
Maeda T, Sakuraba H, Hiraga H, Yoshida S, Kakuta Y, Kikuchi H, Kawaguchi S, Hasui K, Tatsuta T, Chinda D, Mikami T, Fukuda S
- KMID: 2525076
- Intest Res.
- 2022 Jan;20(1):90-100.
- doi: 10.5217/ir.2020.00133
Background/Aims: Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of autoimmune enteropathy with CTLA4 haploinsufficiency
-
Miyazaki H, Hoshi N, Kohashi M, Tokunaga E, Ku Y, Takenaka H, Ooi M, Yamamoto N, Uemura S, Nishimura N, Iijima K, Jimbo K, Okano T, Hoshino A, Imai K, Kanegane H, Kobayashi I, Kodama Y
- KMID: 2525081
- Intest Res.
- 2022 Jan;20(1):144-149.
- doi: 10.5217/ir.2020.00041
Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)... -
- CITED
-
- Close
- SHARE
-
- Close
